Experimental hepatitis b treatment fails to advance
NCT ID NCT02604199
Summary
This study tested whether adding an experimental drug called ARC-520 to standard hepatitis B medications could better reduce signs of the virus in the blood. It involved 58 adults with a specific type of chronic hepatitis B who were already taking standard antiviral pills. The trial was designed to compare ARC-520 against a placebo (dummy treatment) to see if it was safe and more effective, but the study was stopped early and did not complete.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS B are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site 1
Hong Kong, 999077, China
-
Research Site 10
Leipzig, 04103, Germany
-
Research Site 11
Frankfurt, 60590, Germany
-
Research Site 12
Yangsan-si Gyeongnam, 626-770, South Korea
-
Research Site 13
Busan, 602-739, South Korea
-
Research Site 14
Seoul, 110-744, South Korea
-
Research Site 15
Incheon, 405-760, South Korea
-
Research Site 16
Seoul, 120-752, South Korea
-
Research Site 2
Hong Kong, China
-
Research Site 3
Tübingen, 72076, Germany
-
Research Site 4
Leipzig, 4103, Germany
-
Research Site 5
München, 81377, Germany
-
Research Site 6
Ulm, 89081, Germany
-
Research Site 7
Würzburg, 97080, Germany
-
Research Site 8
Hanover, 30625, Germany
-
Research Site 9
Hamburg, 20099, Germany
Conditions
Explore the condition pages connected to this study.